Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Pembrolizumab in Relapsed SCLC
NCT04358237Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC). Started Sep 2020; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04358237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358237.